Sirolimus as a second-line treatment for Graves’ orbitopathy

[1]  M. Nardi,et al.  Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial. , 2021, The lancet. Diabetes & endocrinology.

[2]  W. Wiersinga,et al.  THE 2021 EUROPEAN GROUP ON GRAVES' ORBITOPATHY (EUGOGO) CLINICAL PRACTICE GUIDELINES FOR THE MEDICAL MANAGEMENT OF GRAVES' ORBITOPATHY. , 2021, European journal of endocrinology.

[3]  L. Bartalena,et al.  Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy , 2020, Frontiers in Endocrinology.

[4]  J. Roos,et al.  Inhibition of Fibrotic Contraction by Sirolimus (Rapamycin) in an Ex Vivo Model of Thyroid Eye Disease , 2020, Ophthalmic plastic and reconstructive surgery.

[5]  W. Wiersinga,et al.  Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Graves’ Orbitopathy , 2020, European Thyroid Journal.

[6]  G. Kahaly,et al.  Thyrotropin receptor antibodies and Graves’ orbitopathy , 2020, Journal of Endocrinological Investigation.

[7]  Terry J. Smith,et al.  Teprotumumab for the Treatment of Active Thyroid Eye Disease. , 2020, The New England journal of medicine.

[8]  J. Roos,et al.  Sirolimus (rapamycin) for the targeted treatment of the fibrotic sequelae of Graves’ orbitopathy , 2019, Eye.

[9]  M. Molina-Molina,et al.  Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells , 2018, BMC Pulmonary Medicine.

[10]  G. Kahaly,et al.  Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves’ orbitopathy , 2015, Journal of Endocrinological Investigation.

[11]  A. Tee,et al.  Possible targets for nonimmunosuppressive therapy of Graves' orbitopathy. , 2014, The Journal of clinical endocrinology and metabolism.

[12]  M. Nardi,et al.  Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. , 2012, The Journal of clinical endocrinology and metabolism.

[13]  Pu Li,et al.  Rapamycin Inhibits the mTOR/p70S6K Pathway and Attenuates Cardiac Fibrosis in Adriamycin-induced Dilated Cardiomyopathy , 2012, Thoracic and Cardiovascular Surgeon.

[14]  Lin Sun,et al.  Rapamycin Ameliorates Kidney Fibrosis by Inhibiting the Activation of mTOR Signaling in Interstitial Macrophages and Myofibroblasts , 2012, PloS one.

[15]  S. Singhal,et al.  Cellular Adaptive Inflammation Mediates Airway Granulation in a Murine Model of Subglottic Stenosis , 2011, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[16]  G. Kahaly,et al.  Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. , 2011, The Journal of clinical endocrinology and metabolism.

[17]  W. Braun,et al.  Rapamycin for treatment of refractory dysthyroid compressive optic neuropathy. , 2007, Ophthalmic plastic and reconstructive surgery.

[18]  Terry J. Smith,et al.  Immunoglobulin G from patients with Graves' disease induces interleukin-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T-cell infiltration of the thyroid in autoimmune disease. , 2006, Endocrinology.

[19]  G. Hommel,et al.  Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. , 2005, The Journal of clinical endocrinology and metabolism.

[20]  Terry J. Smith,et al.  Immunoglobulin Activation of T Cell Chemoattractant Expression in Fibroblasts from Patients with Graves’ Disease Is Mediated Through the Insulin-Like Growth Factor I Receptor Pathway1 , 2003, The Journal of Immunology.

[21]  S. Sehgal.  Sirolimus: its discovery, biological properties, and mechanism of action. , 2003, Transplantation proceedings.

[22]  Terry J. Smith,et al.  Igs from Patients with Graves’ Disease Induce the Expression of T Cell Chemoattractants in Their Fibroblasts1 , 2002, The Journal of Immunology.

[23]  C. Terwee,et al.  Development of a disease specific quality of life questionnaire for patients with Graves’ ophthalmopathy: the GO-QOL , 2022 .

[24]  W. Wiersinga,et al.  Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy , 1997, Clinical endocrinology.

[25]  C. Carey.  United States food and drug administration , 2020 .

[26]  R. Goldberg,et al.  Graves' orbitopathy. , 2007, Ophthalmology.